ARTHUR

The Invictus Margin Lending Fund offers investors the ability to take advantage of the volatile nature of the cryptocurrency market without risking direct exposure. The fund aims to maximize interest income on USD and USD equivalents with zero anticipated drawdown risk by taking dollar-based positions on margin lending platforms.

Origin is building a platform that enables the creation of many decentralized marketplaces, allowing buyers and sellers to connect and transact directly on the blockchain. The company is building a set of protocols, developer libraries, and a decentralized application using the Ethereum blockchain and IPFS, with an initial focus on disrupting sharing economy marketplaces. Origin's mission is to reduce or remove transaction fees, promote open and transparent commerce, redistribute value more fairly to buyers and sellers, and empower the 2 billion currently unbanked individuals around the world to participate in digital marketplaces.

Mefy works on a subscription-based model, where the user of MeMe Care subscribes for yearly subscription allowing them any number of tests throughout the year for the cost of just consumables. Through its eConsult feature it connects worldwide doctors to worldwide patients thereby resolving accessibility issues and with its MeMe Edge device, it provides authenticity to the test conducted.

We intend to develop MeconCash into a platform that allows user’s assets to be transferred and traded between different types of services by integrating point reward systems, contents purchase, and settlement, which are currently operated separately between existing services and those under development. To that end, we will build the reward and settlement system, develop the API to connect it with other services, and build an ecosystem that can be used in the on- and off-line real economy. All this will ensure the usability, connectivity, and sustainability of MeconCash. We will develop a variety of mobile-based applications, games, and contents on the platform and link it with such services as online marketplaces where users can purchase products. The reward system used by a service generally invalidates the rewards owned by users when the service is terminated. MeconCash, however, can transform the rewards obtained from using our services into valuable assets. As such, users will be able to fulfill the demand for new services with MeconCash even when the services they use are terminated, make transactions between them, and use the assets in the real economy. We will stabilize the MeconCash ecosystem by developing new blockchain-based businesses and linking it with external services which already exists. Additionally, MeconCash will be available in 70% of ATMs in Korea so that users can directly withdraw MeconCash to fiat money.

Ultrain Technology Limited is the next generation public-blockchain technology venture that focuses on building a high performance decentralized blockchain platform through its programmable tech-infrastructure. Ultrain is committed to construct a responsible and sustainable commercial ecosystem that enables all industrial applications. With its groundbreaking innovations in cryptography and based upon a complete decentralized public network, Ultrain is able to provide multi-folds more advanced technical performance to fundamentally solve the performance and scalability issues comparing to other traditional public blockchain platforms.

Pharmeum is the world's first blockchain-based prescription platform with AI health analytics, which is currently working alongside the National Health Service (NHS) in England. The Pharmeum platform is an inter-operable, decentralised, digital prescription platform running over an intelligent neural network. Empowering patients’ ownership of their medication history, and enabling affordable access to healthcare globally. Medical errors and late diagnoses are minimised by using a permissioned blockchain integrated with artificial intelligence. Pharmeum is an advanced, digitised, health eco-system.The Pharmeum blockchain will improve medicine affordability, minimise errors, and create frictionless, quality care for patients.